HR 9 REGULATORY RISK ASSESSMENT COMPLIANCE WOULD ADD ABOUT $20 MIL. TO FDA SPENDING ON PREMARKET ACTIVITIES, CBO ESTIMATES; HRG HAS SIMILAR PROJECTIONS
This article was originally published in The Gray Sheet
Executive Summary
FDA spending on premarket regulatory activities would increase by about $20 mil. a year if the agency is subjected to the risk assessment requirements under Title III of the "Job Creation and Wage Enhancement Act" (HR 9), the Congressional Budget Office estimates in scoring of the Commerce Committee version of the bill released Feb. 15.